Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 (Q79259921)
Jump to navigation
Jump to search
scientific article published on 17 October 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 |
scientific article published on 17 October 2006 |
Statements
Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study (English)
P Piedbois
D Serin
F Priou
P Laplaige
S Greget
E Angellier
E Teissier
J-F Berdah
M Fabbro
B Valenza
P Herait
V Jehl
17 October 2006